These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 8808907)
1. Long-term intravesical oxybutynin chloride therapy in children with myelodysplasia. Painter KA; Vates TS; Bukowski TP; Fleming P; Freedman AL; Smith CA; Gonzalez R; Perlmutter AD J Urol; 1996 Oct; 156(4):1459-62. PubMed ID: 8808907 [TBL] [Abstract][Full Text] [Related]
2. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population. Palmer LS; Zebold K; Firlit CF; Kaplan WE J Urol; 1997 Feb; 157(2):638-40. PubMed ID: 8996387 [TBL] [Abstract][Full Text] [Related]
3. [The use of intravesical oxybutynin hydrochloride in patients with neurogenic bladder managed by intermittent catheterization]. Yokoyama O; Ishiura Y; Nakamura Y; Ohkawa M Hinyokika Kiyo; 1995 Jul; 41(7):521-4. PubMed ID: 7668182 [TBL] [Abstract][Full Text] [Related]
4. [Topical treatment with oxybutynin chloride in neurogenic incontinence]. López Pereira P; Martínez MJ; Muguerza R; Jaureguizar E Cir Pediatr; 1993 Jan; 6(1):29-31. PubMed ID: 8499234 [TBL] [Abstract][Full Text] [Related]
5. Intravesical instillation of oxybutynin hydrochloride therapy for patients with a neuropathic bladder. Mizunaga M; Miyata M; Kaneko S; Yachiku S; Chiba K Paraplegia; 1994 Jan; 32(1):25-9. PubMed ID: 8015832 [TBL] [Abstract][Full Text] [Related]
6. [Intravesical oxybutynin in children with meningomyelocele. Efficient treatment with few side-effects]. Von Zweigbergk M; Nordin B; Jonsson S Lakartidningen; 1996 Oct; 93(41):3573-6. PubMed ID: 8965514 [No Abstract] [Full Text] [Related]
7. Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction. Franco I; Horowitz M; Grady R; Adams RC; de Jong TP; Lindert K; Albrecht D J Urol; 2005 Jan; 173(1):221-5. PubMed ID: 15592080 [TBL] [Abstract][Full Text] [Related]
8. Expanded followup of intravesical oxybutynin chloride use in children with neurogenic bladder. Kaplinsky R; Greenfield S; Wan J; Fera M J Urol; 1996 Aug; 156(2 Pt 2):753-6. PubMed ID: 8683776 [TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters. Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114 [TBL] [Abstract][Full Text] [Related]
10. Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin. Di Stasi SM; Giannantoni A; Navarra P; Capelli G; Storti L; Porena M; Stephen RL J Urol; 2001 Dec; 166(6):2232-6. PubMed ID: 11696741 [TBL] [Abstract][Full Text] [Related]
11. The use of intravesical oxybutynin chloride in children with neurogenic bladder. Greenfield SP; Fera M J Urol; 1991 Aug; 146(2 ( Pt 2)):532-4. PubMed ID: 1861294 [TBL] [Abstract][Full Text] [Related]